Edema Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Phase (Phase I, Phase II, Phase III, Phase IV), By Participants (Pediatrics, Adults, Geriatrics), By Sponsor (Pharmaceutical Companies, Academic Institutions, Government Bodies), By Type (Systemic Edema, Localized Edema), By Region and Competition, 2019-2029F

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2025-2029

Market Size (2023)

USD 852.52 Million

CAGR (2024-2029)

3.25%

Fastest Growing Segment

Phase II

Largest Market

     North America

Market Size (2029)

USD 1,004.03 Million

 

Market Overview

Global Edema Clinical Trials Market was valued at USD 852.52 Million in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 3.25% through 2029. Edema, characterized by the accumulation of excess fluid in the body's tissues, is a common medical condition with numerous underlying causes. From heart disease to kidney dysfunction, edema can be a symptom of various health issues. As medical science continues to advance, there is a growing need to develop effective treatments and therapies for edema. Clinical trials play a pivotal role in this endeavor, providing a platform for testing and validating potential solutions. Clinical trials are research studies that investigate new medical treatments, therapies, and drugs to determine their safety, efficacy, and potential side effects. These trials are essential for advancing the field of medicine and improving patient care. Edema can be caused by a wide range of underlying conditions, and not all cases respond well to current treatments. Clinical trials serve as a breeding ground for innovative approaches to treating edema, potentially improving the quality of life for patients. Through clinical trials, researchers can gain a deeper understanding of the mechanisms behind edema. This knowledge can lead to more targeted and effective treatments in the future. Clinical trials allow for personalized treatment approaches, ensuring that patients receive the most appropriate care for their specific condition and needs.

Key Market Drivers

Rising Prevalence of Edema-Related Disorders is Driving the Global Edema Clinical Trials Market

Edema, commonly known as swelling, is a condition characterized by an abnormal accumulation of fluid in the body's tissues. Edema can affect any part of the body and can result from various underlying causes, including heart failure, kidney disease, venous insufficiency, pregnancy, and certain medications. Edema-related disorders pose a significant burden on global healthcare systems, and as the prevalence of these conditions continues to rise, clinical trials are becoming instrumental in advancing the understanding and treatment of edema-related disorders. Edema-related disorders are becoming increasingly prevalent worldwide. This is due to several factors, including an aging population, the rising incidence of chronic diseases, and changing lifestyles. Chronic conditions like heart failure, diabetes, and obesity can lead to fluid retention and edema, thereby contributing to the growing burden of these disorders. The consequences of untreated edema can be severe, including impaired mobility, discomfort, and an increased risk of complications, making it essential to address this issue comprehensively. Clinical trials play a pivotal role in expanding the knowledge and treatment options for edema-related disorders. These trials are research studies that involve human participants and are designed to investigate new therapies, drugs, or interventions for specific medical conditions. In the context of edema, clinical trials are essential for the development of innovative treatments and therapies to alleviate symptoms and improve the quality of life for individuals affected by these disorders.

As the prevalence of edema-related disorders rises, there is a growing demand for more effective treatments. Clinical trials provide a platform for researchers to test and validate new interventions, helping to improve patient outcomes. The field of medical research is continually evolving, with new insights into the underlying mechanisms of edema and the development of innovative treatment approaches. Clinical trials are critical in translating these scientific discoveries into practical treatments. Regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) encourage and support clinical trials as part of the drug approval process. This regulatory support accelerates the development and commercialization of new therapies. Pharmaceutical and biotechnology companies are investing significantly in research and development to address edema-related disorders. This has led to a surge in clinical trials, as these companies seek to bring new treatments to market. With a growing emphasis on patient-centred healthcare, clinical trials offer patients the opportunity to access cutting-edge treatments and contribute to scientific advancements. This has increased patient participation in clinical trials.

Growing Investment in Research and Development is Driving the Global Edema Clinical Trials Market

Research and development (R&D) have always played a pivotal role in advancing medical science and improving patient care. The healthcare sector continually strives to discover innovative solutions to address prevalent health issues, such as edema. Edema, characterized by the accumulation of excess fluid in body tissues, can be a symptom of various medical conditions. With the increasing focus on R&D, there has been a notable surge in clinical trials related to edema treatment and management. This trend is driving the global Edema Clinical Trials Market, revolutionizing the way we understand, diagnose, and treat edema. Advances in medical technology and diagnostics have enabled researchers to better understand the underlying causes of edema. This has paved the way for the development of more targeted and effective treatments. Both public and private sectors are investing significantly in R&D, which translates into more resources for clinical trials. Pharmaceutical companies, research institutions, and government agencies are allocating substantial funds to edema-related research.

As the global population ages and the prevalence of chronic diseases increases, the demand for effective edema management solutions is on the rise. This demand motivates further R&D and clinical trials to meet these healthcare challenges. Collaboration between pharmaceutical companies, academic institutions, and healthcare providers is fostering a conducive environment for edema research. These partnerships encourage the sharing of knowledge and resources, ultimately expediting the development of new therapies.

The growing investment in R&D is significantly impacting the Edema Clinical Trials Market. The influx of resources has expanded the scope of clinical trials for edema, allowing for a more diverse range of studies. This results in a broader portfolio of potential treatments and diagnostic tools. As clinical trials become more sophisticated and data-driven, the likelihood of discovering effective treatments and management strategies for edema is increasing. Patients can expect better outcomes and a higher quality of life. Increased investment in R&D fosters greater awareness and participation in clinical trials. Patients are more willing to engage in trials, contributing to the body of knowledge about edema. The Edema Clinical Trials Market is experiencing substantial growth as a result of increased R&D investment. This growth encompasses not only the development of new therapies but also the expansion of supportive services, such as patient recruitment and data management solutions.




Download Free Sample Report

Key Market Challenges

Patient Recruitment and Retention

One of the most significant challenges in edema clinical trials is patient recruitment and retention. Edema affects a diverse population, making it essential to find and enroll a representative sample of participants. Many individuals with edema may be unwilling to participate in clinical trials due to the perceived risks, time commitments, or concerns about the investigational nature of the treatments.

To address this challenge, clinical trial organizers must employ comprehensive recruitment strategies, collaborate with patient advocacy groups, and develop clear communication channels with potential participants. Maintaining patient engagement throughout the trial, addressing their concerns, and ensuring they complete the trial is equally crucial to obtaining meaningful results.

Ethical and Regulatory Considerations

Clinical trials in the edema space must adhere to rigorous ethical and regulatory standards. As edema can be a symptom of underlying medical conditions, conducting trials can raise ethical concerns about treating the root cause or focusing solely on edema management. Researchers must carefully navigate these issues to ensure that the trial design is both ethical and practical.

Regulatory hurdles can also be challenging, with varying approval processes in different regions. Streamlining the regulatory process to ensure that trials can be conducted efficiently and that results can be translated into clinical practice is essential.

Placebo Effect

The placebo effect is a well-documented phenomenon in clinical trials. In edema trials, where visible and subjective symptoms like swelling and discomfort are common, patients' beliefs and expectations can significantly impact trial outcomes. Distinguishing the actual efficacy of a treatment from the placebo effect can be challenging, potentially leading to skewed results.

To mitigate the placebo effect, researchers must design trials with robust controls, including double-blind, randomized studies and validated measurement tools. Statistical methods that account for placebo responses can also help identify the true benefits of a treatment.

Limited Therapeutic Options

The limited availability of approved edema treatments poses a challenge to clinical trials. Edema is often treated with diuretics or lifestyle modifications, leaving little room for novel interventions. Developing new therapeutic options that significantly improve patient outcomes and meet regulatory requirements can be a lengthy and expensive process.

To overcome this challenge, researchers should explore innovative treatment modalities such as advanced pharmacotherapies, targeted therapies, and gene-based interventions. Collaboration between academic institutions, pharmaceutical companies, and medical device manufacturers can help diversify the therapeutic landscape for edema.

Data Collection and Analysis

The effective collection and analysis of clinical trial data are vital for establishing treatment efficacy. However, edema symptoms can be subjective and vary among individuals. Reliable and standardized data collection methods are essential to ensure the accuracy and consistency of trial results.

Utilizing electronic health records, wearable devices, and advanced imaging technologies can enhance data collection. Data analysis methods, including machine learning and artificial intelligence, can provide valuable insights into patient responses, further improving the quality of clinical trials in the edema space.

Key Market Trends

Rising Technological Advancements

The global healthcare industry is in the midst of a technological revolution, and this transformation is extending its influence to various medical conditions, including edema. Edema is a medical condition characterized by the accumulation of excess fluid in the body's tissues, leading to swelling and discomfort. Over the years, clinical trials have played a crucial role in the development of treatments and therapies for edema. With advancements in technology, clinical trials in the field of edema research are becoming more efficient, accurate, and patient-centric. One of the primary ways technology is advancing edema clinical trials is through the use of data analytics and artificial intelligence (AI). These tools can process large datasets to identify trends, predict patient responses to treatment, and optimize trial design. Machine learning algorithms can assist researchers in making more informed decisions, reducing trial durations, and ultimately speeding up the development of new therapies. Wearable devices and remote monitoring technologies are revolutionizing how clinical trials are conducted. Patients can now participate in trials from the comfort of their homes, reducing the need for frequent clinic visits. Devices such as smartwatches, connected scales, and mobile apps enable real-time data collection, providing researchers with a more comprehensive view of a patient's condition and treatment progress.

Telemedicine has become an essential tool for edema clinical trials, allowing researchers to conduct virtual visits, monitor patient progress, and provide immediate medical care when necessary. This not only increases patient convenience but also expands the reach of clinical trials to a more diverse and global patient population. Technological advancements in 3D printing have opened new doors for personalized medicine. Researchers can now create patient-specific models of edematous tissues to better understand the condition's underlying mechanisms and test potential treatments. This approach can lead to more precise and effective therapies tailored to individual patient needs. Blockchain technology is being used to enhance the security and transparency of clinical trial data. By using blockchain, researchers can ensure the integrity of data, protect patient privacy, and streamline the sharing of information among stakeholders, including pharmaceutical companies, regulatory agencies, and healthcare providers.

Segmental Insights

Phase Insights

Based on Phase, Phase II have emerged as the fastest growing segment in the Global Edema Clinical Trials Market in 2023. Phase II clinical trials are an integral part of the drug development process, serving as a bridge between Phase I (safety and dosage) and Phase III (efficacy confirmation). Phase II trials are primarily designed to evaluate the treatment's effectiveness. In the case of edema, this phase is critical for determining whether the investigational therapy can alleviate fluid retention and improve patient outcomes. Researchers in Phase II trials can fine-tune dosages and administration schedules to identify the most effective and safest treatment regimen. This phase helps strike the right balance between effectiveness and potential side effects. Phase II trials typically involve a more extensive and diverse patient population, providing a broader perspective on how the treatment affects different individuals. This diversity enhances the generalizability of the results. While Phase II primarily focuses on effectiveness, it also continues to monitor safety. This dual approach ensures that promising treatments do not have unexpected adverse effects, which is essential for regulatory approval. By conducting Phase II trials, researchers can assess whether the treatment is practical for widespread use in real-world clinical settings, contributing to better decision-making for future development.

Participants Insights

Based on Participants, Adults have emerged as the fastest growing segment in Global Edema Clinical Trials Market during the forecast period. Edema is more prevalent among adults compared to children or the elderly. The condition often manifests as a secondary symptom of other health issues, such as heart disease, diabetes, or obesity, which are more common in the adult population. Therefore, clinical trials primarily focusing on adults are better suited to address the root causes and treatment of edema. Many clinical trials for edema aim to understand and treat the underlying causes of the condition. These causes often require interventions or therapies that are more relevant to adults, such as dietary changes, lifestyle modifications, or advanced medical procedures. Therefore, focusing on adult participants is a logical choice to tailor treatment strategies. Clinical trials involving pediatric participants require stricter ethical oversight and involve unique considerations due to the vulnerability of children. While pediatric edema research is essential, it often necessitates separate protocols and approvals, making it a more complex and time-consuming process. This factor can encourage researchers to prioritize adult participants when seeking efficient solutions to edema.




Download Free Sample Report

Regional Insights

Based on Region, North America have emerged as the dominating region in the Global Edema Clinical Trials Market in 2023. North America boasts a robust and well-established research infrastructure, including world-renowned medical institutions, universities, and healthcare facilities. These institutions often collaborate with pharmaceutical companies to conduct edema clinical trials, ensuring a high standard of research. North America is at the forefront of medical innovation and technology. With access to cutting-edge equipment and research tools, researchers in the region can conduct comprehensive clinical trials, offering new and advanced treatment options for edema.

Recent Developments

  • In February 2024, Kyowa Kirin Co., Ltd. announced the initiation of a Phase 2 clinical trial, which is a multi-center, randomized, double-masked, parallel group study, focusing on tivozanib eye drops (KHK4951). This trial aims to assess the effectiveness and safety of KHK4951 in treating patients with diabetic macular edema (DME). Tivozanib, the active component of KHK4951, is a small-molecule inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3 tyrosine kinase (TKI), developed by Kyowa Kirin. KHK4951, a newly formulated nano-crystalized version of tivozanib eye drops, is designed to efficiently target the posterior ocular tissues. It is being explored as a potential therapeutic option for both neovascular (wet) age-related macular degeneration (nAMD) and DME. Currently, an oral form of tivozanib, marketed as FOTIVDA in the U.S. by AVEO Oncology, an LG Chem Company, and in Europe by EUSA Pharma (UK) Ltd., is available for another medical indication.

Key Market Players

  • Otsuka Holdings Co. Ltd.
  • Novartis AG
  • Genentech, Inc.
  • Johnson & Johnson Services, Inc. 
  • Merck & Co., Inc.
  • Sanofi S.A.
  • AstraZeneca plc
  • Bristol Myers Squibb India Pvt. Ltd.
  • GlaxoSmithKline plc
  • AbbVie Inc.

By Phase

By Participants

By Sponsor

By  Type

By Region
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
  • Pediatrics
  • Adults
  • Geriatrics
  • Pharmaceutical Companies
  • Academic Institutions
  • Government Bodies
  • Systemic Edema
  • Localized Edema
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa


Report Scope:

In this report, the Global Edema Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Edema Clinical Trials Market, By Phase:

o Phase I

o Phase II

o Phase III

o Phase IV

  • Edema Clinical Trials Market, By Participants:

o Pediatrics

o Adults

o Geriatrics

  • Edema Clinical Trials Market, By Sponsor:

o Pharmaceutical Companies

o Academic Institutions

o Government Bodies

  • Edema Clinical Trials Market, By Type:

o Systemic Edema

o Localized Edema

  • Edema Clinical Trials Market, By Region:

o North America

§ United States

§ Canada

§ Mexico

o Europe

§ France

§ United Kingdom

§ Italy

§ Germany

§ Spain

o Asia Pacific

§ China

§ India

§ Japan

§ Australia

§ South Korea

o South America

§ Brazil

§ Argentina

§ Colombia

o Middle East & Africa

§ South Africa

§ Saudi Arabia

§ UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Edema Clinical Trials Market.

Available Customizations:

Global Edema Clinical Trials Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Edema Clinical Trials Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]             

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Global Edema Clinical Trials Market Outlook

4.1.  Market Size & Forecast

4.1.1.     By Value

4.2.  Market Share & Forecast

4.2.1.     By Phase (Phase I, Phase II, Phase III, Phase IV)

4.2.2.     By Participants (Pediatrics, Adults, Geriatrics)

4.2.3.     By Sponsor (Pharmaceutical Companies, Academic Institutions, Government Bodies)

4.2.4.     By Type (Systemic Edema, Localized Edema)

4.2.5.     By Region

4.2.6.     By Company (2023)

4.3.  Market Map

4.3.1.     By Phase

4.3.2.     By Participants

4.3.3.     By Sponsor

4.3.4.     By Type

4.3.5.     By Region

5.    Asia Pacific Edema Clinical Trials Market Outlook

5.1.  Market Size & Forecast

5.1.1.     By Value

5.2.  Market Share & Forecast

5.2.1.     By Phase

5.2.2.     By Participants

5.2.3.     By Sponsor

5.2.4.     By Type

5.2.5.     By Country

5.3.  Asia Pacific: Country Analysis

5.3.1.     China Edema Clinical Trials Market Outlook

5.3.1.1.         Market Size & Forecast

5.3.1.1.1.             By Value

5.3.1.2.         Market Share & Forecast

5.3.1.2.1.             By Phase

5.3.1.2.2.             By Participants

5.3.1.2.3.             By Sponsor

5.3.1.2.4.             By Type

5.3.2.     India Edema Clinical Trials Market Outlook

5.3.2.1.         Market Size & Forecast

5.3.2.1.1.             By Value

5.3.2.2.         Market Share & Forecast

5.3.2.2.1.             By Phase

5.3.2.2.2.             By Participants

5.3.2.2.3.             By Sponsor

5.3.2.2.4.             By Type

5.3.3.     Australia Edema Clinical Trials Market Outlook

5.3.3.1.         Market Size & Forecast

5.3.3.1.1.             By Value

5.3.3.2.         Market Share & Forecast

5.3.3.2.1.             By Phase

5.3.3.2.2.             By Participants

5.3.3.2.3.             By Sponsor

5.3.3.2.4.             By Type

5.3.4.     Japan Edema Clinical Trials Market Outlook

5.3.4.1.         Market Size & Forecast

5.3.4.1.1.             By Value

5.3.4.2.         Market Share & Forecast

5.3.4.2.1.             By Phase

5.3.4.2.2.             By Participants

5.3.4.2.3.             By Sponsor

5.3.4.2.4.             By Type

5.3.5.     South Korea Edema Clinical Trials Market Outlook

5.3.5.1.         Market Size & Forecast

5.3.5.1.1.             By Value

5.3.5.2.         Market Share & Forecast

5.3.5.2.1.             By Phase

5.3.5.2.2.             By Participants

5.3.5.2.3.             By Sponsor

5.3.5.2.4.             By Type

6.    Europe Edema Clinical Trials Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Phase

6.2.2.     By Participants

6.2.3.     By Sponsor

6.2.4.     By Type

6.2.5.     By Country

6.3.  Europe: Country Analysis

6.3.1.     France Edema Clinical Trials Market Outlook

6.3.1.1.         Market Size & Forecast

6.3.1.1.1.             By Value

6.3.1.2.         Market Share & Forecast

6.3.1.2.1.             By Phase

6.3.1.2.2.             By Participants

6.3.1.2.3.             By Sponsor

6.3.1.2.4.             By Type

6.3.2.     Germany Edema Clinical Trials Market Outlook

6.3.2.1.         Market Size & Forecast

6.3.2.1.1.             By Value

6.3.2.2.         Market Share & Forecast

6.3.2.2.1.             By Phase

6.3.2.2.2.             By Participants

6.3.2.2.3.              By Sponsor

6.3.2.2.4.             By Type

6.3.3.     Spain Edema Clinical Trials Market Outlook

6.3.3.1.         Market Size & Forecast

6.3.3.1.1.             By Value

6.3.3.2.         Market Share & Forecast

6.3.3.2.1.             By Phase

6.3.3.2.2.             By Participants

6.3.3.2.3.             By Sponsor

6.3.3.2.4.             By Type

6.3.4.     Italy Edema Clinical Trials Market Outlook

6.3.4.1.         Market Size & Forecast

6.3.4.1.1.             By Value

6.3.4.2.         Market Share & Forecast

6.3.4.2.1.             By Phase

6.3.4.2.2.             By Participants

6.3.4.2.3.              By Sponsor

6.3.4.2.4.             By Type

6.3.5.     United Kingdom Edema Clinical Trials Market Outlook

6.3.5.1.         Market Size & Forecast

6.3.5.1.1.             By Value

6.3.5.2.         Market Share & Forecast

6.3.5.2.1.             By Phase

6.3.5.2.2.             By Participants

6.3.5.2.3.             By Sponsor

6.3.5.2.4.             By Type

7.    North America Edema Clinical Trials Market Outlook

7.1.  Market Size & Forecast

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Phase

7.2.2.     By Participants

7.2.3.     By Sponsor

7.2.4.     By Type

7.2.5.     By Country

7.3.  North America: Country Analysis

7.3.1.     United States Edema Clinical Trials Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Phase

7.3.1.2.2.             By Participants

7.3.1.2.3.             By Sponsor

7.3.1.2.4.             By Type

7.3.2.     Mexico Edema Clinical Trials Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Phase

7.3.2.2.2.             By Participants

7.3.2.2.3.             By Sponsor

7.3.2.2.4.             By Type

7.3.3.     Canada Edema Clinical Trials Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Phase

7.3.3.2.2.             By Participants

7.3.3.2.3.              By Sponsor

7.3.3.2.4.             By Type

8.    South America Edema Clinical Trials Market Outlook

8.1.  Market Size & Forecast

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Phase

8.2.2.     By Participants

8.2.3.     By Sponsor

8.2.4.     By Type

8.2.5.     By Country

8.3.  South America: Country Analysis

8.3.1.     Brazil Edema Clinical Trials Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Phase

8.3.1.2.2.             By Participants

8.3.1.2.3.             By Sponsor

8.3.1.2.4.             By Type

8.3.2.     Argentina Edema Clinical Trials Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Phase

8.3.2.2.2.             By Participants

8.3.2.2.3.              By Sponsor

8.3.2.2.4.             By Type

8.3.3.     Colombia Edema Clinical Trials Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Phase

8.3.3.2.2.             By Participants

8.3.3.2.3.             By Sponsor

8.3.3.2.4.             By Type

9.    Middle East and Africa Edema Clinical Trials Market Outlook

9.1.  Market Size & Forecast

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Phase

9.2.2.     By Participants

9.2.3.     By Sponsor

9.2.4.     By Type

9.2.5.     By Country

9.3.  MEA: Country Analysis

9.3.1.     South Africa Edema Clinical Trials Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Phase

9.3.1.2.2.             By Participants

9.3.1.2.3.             By Sponsor

9.3.1.2.4.             By Type

9.3.2.     Saudi Arabia Edema Clinical Trials Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Phase

9.3.2.2.2.             By Participants

9.3.2.2.3.             By Sponsor

9.3.2.2.4.             By Type

9.3.3.     UAE Edema Clinical Trials Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Phase

9.3.3.2.2.             By Participants

9.3.3.2.3.              By Sponsor

9.3.3.2.4.             By Type

10.  Market Dynamics

10.1.              Drivers

10.2.              Challenges

11.  Market Trends & Developments

11.1.              Recent Developments

11.2.              Product Launches

11.3.              Mergers & Acquisitions

12.  Global Edema Clinical Trials Market: SWOT Analysis

13.  Porter’s Five Forces Analysis

13.1.              Competition in the Industry

13.2.              Potential of New Entrants

13.3.              Power of Suppliers

13.4.              Power of Customers

13.5.              Threat of Substitute Product

14.  Competitive Landscape

14.1.          Otsuka Holdings Co. Ltd.

14.1.1.           Business Overview

14.1.2.           Company Snapshot

14.1.3.           Products & Services

14.1.4.           Financials (In case of listed)

14.1.5.           Recent Developments

14.1.6.           SWOT Analysis

14.2.             Novartis AG

14.3.            Genentech, Inc.

14.4.            Johnson & Johnson Services, Inc. 

14.5.            Merck & Co., Inc.

14.6.            Sanofi S.A.

14.7.            AstraZeneca plc

14.8.            Bristol Myers Squibb India Pvt. Ltd.

14.9.            GlaxoSmithKline plc

14.10.         AbbVie Inc.

15.  Strategic Recommendations

16. About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Edema Clinical Trials Market was estimated to be USD 852.52 Million in 2023.

down-arrow

Patient recruitment and retention to undergo edema clinical trials are the major challenges which hinder the growth of Global Edema Clinical Trials Market.

down-arrow

Otsuka Holdings Co. Ltd. , Novartis AG, Genentech, Inc. were the top players operating in the Global Edema Clinical Trials Market in 2023.

down-arrow

Rising prevalence of edema-related disorders and growing investment in research and development are the major drivers for the Global Edema Clinical Trials Market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Edema Clinical Trials Market to Grow with a CAGR of 3.25% through 2029

Jun, 2024

Rising prevalence of edema-related disorders and growing investment in research and development are factors driving the Global Edema Clinical Trials Market in the forecast period, 2025-2029.

Why Choose Us